**Mini Review**
Volume 15:02, 2024

Journal of Cytology & Histology

ISSN: 2157-7099 Open Access

# Histopathological Changes in Neurodegenerative Diseases: Implications for Diagnosis and Therapy

**Marian Fassun***

*Department of Pathology and Genomic Medicine, University of Freiburg, Fahnenbergplatz, 79085 Freiburg im Breisgau, Germany*

## Abstract

Neurodegenerative diseases represent a significant and growing burden on global healthcare systems, affecting millions of individuals worldwide. Understanding the histopathological changes associated with these diseases is crucial for accurate diagnosis and the development of effective therapeutic strategies. This review explores the histopathological hallmarks of major neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. We discuss the molecular and cellular mechanisms underlying these histopathological changes, their implications for disease diagnosis, and current and emerging therapeutic approaches targeting these pathological features.

**Keywords:** Neurodegenerative diseases • Neurofibrillary tangles • Alzheimer's disease

## Introduction

Neurodegenerative diseases are characterized by progressive degeneration of neurons, leading to cognitive decline, motor dysfunction, and other neurological symptoms. Histopathological examination of brain tissue remains essential for the definitive diagnosis of these diseases. Understanding the specific histopathological changes associated with each condition is crucial for accurate diagnosis and the development of targeted therapies. AD is characterized by the accumulation of beta-amyloid plaques and neurofibrillary tangles in the brain. Beta-amyloid plaques are extracellular deposits primarily composed of amyloid-beta peptides, while NFTs are intracellular aggregates of hyperphosphorylated tau protein. These histopathological changes disrupt neuronal function and are associated with synaptic loss and neuroinflammation.

Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects cognitive functions, including memory, thinking, and behavior. It is the most common cause of dementia among older adults. AD is characterized by the accumulation of beta-amyloid plaques, which are extracellular deposits primarily composed of amyloid-beta peptides. These plaques disrupt neuronal function and contribute to synaptic loss and neuroinflammation.

Another hallmark of AD is the presence of neurofibrillary tangles, which are intracellular aggregates of hyperphosphorylated tau protein. NFTs destabilize microtubules in neurons, impairing cellular transport and leading to cell death. AD is associated with progressive neuronal loss, particularly in brain regions important for memory and cognition, such as the hippocampus and cerebral cortex. This neuronal loss leads to brain atrophy, which can be visualized on neuroimaging studies. AD involves disruptions in neurotransmitter systems, particularly the cholinergic system, which plays a key role in learning and memory. Decreased levels of acetylcholine contribute to cognitive decline in AD.

While most cases of AD occur sporadically, genetic factors, such as mutations in the APP, PSEN1, and PSEN2 genes, can increase the risk of developing the disease. Environmental factors, such as cardiovascular health and lifestyle factors, also play a role in AD risk. Symptoms of AD typically include memory loss, confusion, difficulty with language and communication, impaired judgment, and changes in mood and behavior. As the disease progresses, individuals may experience severe cognitive decline and loss of independence. Diagnosis of AD is based on clinical evaluation, including medical history, cognitive assessments, and neuroimaging studies. Biomarkers such as beta-amyloid and tau protein levels in cerebrospinal fluid or PET imaging can aid in diagnosis and staging of the disease.

## Literature Review

Currently, there is no cure for Alzheimer's disease, but medications such as cholinesterase inhibitors and memantine may help manage symptoms and slow disease progression in some individuals. Non-pharmacological interventions, such as cognitive stimulation and lifestyle modifications, can also improve quality of life for people with AD [1-3]. In summary, Alzheimer's disease is a complex neurodegenerative disorder characterized by progressive cognitive decline, neuronal loss, and the accumulation of pathological proteins in the brain. Ongoing research aims to better understand the underlying mechanisms of the disease and develop effective treatments to delay or prevent its progression. PD is characterized by the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies, which are intracellular aggregates primarily composed of alpha-synuclein protein. In addition to Lewy bodies, PD is associated with mitochondrial dysfunction, oxidative stress, and neuroinflammation.

Parkinson's disease is a progressive neurodegenerative disorder that primarily affects movement. It is characterized by the loss of dopamine-producing neurons in the substantia nigra region of the brain. PD is associated with the degeneration of dopaminergic neurons in the substantia nigra, leading to a decrease in dopamine levels in the brain. Dopamine is a neurotransmitter involved in the regulation of movement and coordination. Parkinson's disease is characterized by the presence of abnormal protein aggregates called Lewy bodies within neurons. These aggregates are primarily composed of alpha-synuclein protein and can disrupt cellular function and contribute to neuronal death.

## Discussion

The hallmark motor symptoms of PD include bradykinesia (slowness of movement), rigidity (stiffness), resting tremor (tremor that occurs at rest), and postural instability (difficulty with balance and coordination). These symptoms typically worsen over time and can significantly impair daily activities. PD can also cause a range of non-motor symptoms, including cognitive impairment, depression, anxiety, sleep disturbances, and autonomic dysfunction (such

***Address for Correspondence:** Marian Fassun, Department of Pathology and Genomic Medicine, University of Freiburg, Fahnenbergplatz, 79085 Freiburg im Breisgau, Germany, E-mail: marianfassun@gmail.com*



**Received:** 01 March, 2024, Manuscript No. jch-24-135922; **Editor Assigned:** 02 March, 2024, PreQC No. P-135922; **Reviewed:** 16 March, 2024, QC No. Q-135922; **Revised:** 22 March, 2024, Manuscript No. R-135922; **Published:** 30 March, 2024, DOI: 10.37421/2157-7099.2024.15.738

as constipation and orthostatic hypotension). Other secondary features of PD may include freezing of gait, micrographia (small handwriting), reduced facial expression (masked facies), and difficulty with speech and swallowing. Diagnosis of Parkinson's disease is primarily based on clinical evaluation, including the presence of characteristic motor symptoms and response to dopaminergic medication [4,5].

Neuroimaging studies such as MRI or DaTscan may be used to support diagnosis and rule out other conditions. While there is currently no cure for Parkinson's disease, treatment aims to manage symptoms and improve quality of life. Medications such as levodopa (which is converted to dopamine in the brain), dopamine agonists, and MAO-B inhibitors can help alleviate motor symptoms. Deep brain stimulation surgery may be considered for individuals with advanced PD who do not respond well to medication. Research and Future Directions: Ongoing research into the underlying causes of Parkinson's disease aims to develop disease-modifying therapies that can slow or halt disease progression.

This includes investigations into neuroprotective strategies, stem cell therapy, gene therapy, and novel drug targets. In summary, Parkinson's disease is a complex neurological disorder characterized by dopaminergic neuron loss, motor and non-motor symptoms, and the presence of Lewy bodies. While current treatments can help manage symptoms, there is a need for further research to develop more effective therapies and ultimately find a cure for this debilitating condition. HD is caused by a CAG repeat expansion in the huntingtin gene, leading to the production of mutant huntingtin protein. Histopathological features of HD include neuronal loss, particularly in the striatum, as well as the presence of intranuclear inclusions containing mutant huntingtin protein [6].

ALS is characterized by the degeneration of motor neurons in the brain and spinal cord. Histopathological features of ALS include neuronal loss, gliosis, and the presence of proteinaceous inclusions, such as TDP-43 or FUS protein aggregates. The histopathological changes observed in neurodegenerative diseases reflect underlying molecular and cellular abnormalities, including protein misfolding, aggregation, and dysfunction, as well as impaired proteostasis, mitochondrial dysfunction, and neuroinflammation.

These mechanisms contribute to neuronal dysfunction, synaptic loss, and ultimately cell death. Histopathological examination remains the gold standard for diagnosing neurodegenerative diseases, particularly in postmortem brain tissue. Advances in imaging techniques, such as positron emission tomography and magnetic resonance imaging, can also provide valuable information for early diagnosis and disease monitoring. Anti-amyloid and anti-tau therapies for AD. Alpha-synuclein targeting therapies for PD. Gene silencing and protein degradation strategies for HD. Protein clearance and neuroprotection strategies for ALS.

## Conclusion

Histopathological examination plays a critical role in understanding the pathogenesis of neurodegenerative diseases and guiding therapeutic interventions. Advances in our understanding of the molecular mechanisms underlying histopathological changes have led to the development of promising therapeutic strategies, although significant challenges remain in translating these findings into effective treatments. Further research is needed to develop disease-modifying therapies that target the underlying causes of neurodegeneration and improve outcomes for patients with these devastating conditions.

## Acknowledgement

None.

## Conflict of Interest

There are no conflicts of interest by author.

## References

1. Liebig, Catherine, Gustavo Ayala, Jonathan A. Wilks and David H. Berger, et al. "Perineural invasion in cancer: A review of the literature." *Int J Cancer* 115 (2009): 3379-3391.
2. Chen, Wei, Shaozhong Dong, Jun Zhou and Moyi Sun, et al. "Investigation of myoepithelial cell differentiation into Schwann-like cells in salivary adenoid cystic carcinoma associated with perineural invasion." *Mol Med Rep* 6 (2012): 755-759.
3. Bakst, Richard L., Christine M. Glastonbury, Upendra Parvathaneni and Nora Katabi, et al. "Perineural invasion and perineural tumor spread in head and neck cancer."*Int J Radiat Oncol* 103 (2019): 1109-1124.
4. Zhang, Ze, Ruoyan Liu, Rui Jin and Yanling Fan, et al. "Integrating clinical and genetic analysis of perineural invasion in head and neck squamous cell carcinoma." *Front Oncol* 9 (2019): 434.
5. Liu, Xiaohao, Xiaojun Yang, Chaoning Zhan and Yan Zhang, et al. "Perineural invasion in adenoid cystic carcinoma of the salivary glands: Where we are and where we need to go." *Front Oncol* 10 (2020): 1493.
6. Ghahremani, Parmida, Yanyun Li, Arie Kaufman and Rami Vanguri, et al. "Deep learning-inferred multiplex immunofluorescence for immunohistochemical image quantification." *Nat Mach Intell* 4 (2022): 401-412.

**How to cite this article:** Fassun, Marian. "Histopathological Changes in Neurodegenerative Diseases: Implications for Diagnosis and Therapy." *J Cytol Histol* 15 (2024): 738.